GSK today announced a series of investments totalling approximately �200 million that will support the delivery of the company's pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
GlaxoSmithKline plc (the Company) announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 1 May 2013 it purchased 692,000 of its Ordinary Shares of 25 pence each (Shares) on 10 December ...
GlaxoSmithKline is to invest another 200 million pounds ($330 million) on advanced manufacturing in Britain, the company said on Wednesday, underlining the draw of a tax break designed to encourage research and development.
GlaxoSmithKline Plc (GSK) Chief Executive Officer Andrew Witty joined U.K. Prime Minister David Cameron on a trade mission to China today as his company faces a corruption investigation in the country.
A common theme striking big-cap pharma plays such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been the widescale loss of patent on key products, a scenario that has weighed significantly on revenues in recent times.